Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology

NEXT STORY
TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting
PREV STORY
Immunoassay Market Worth $46.5 Billion by 2028, Growing at a CAGR of 7.5% From 2021- Exclusive Report by Meticulous Research®
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Stemline Therapeutics Announces Positive FDA Meeting and Agreement on Expedited Pathway to Full Approval of SL-401 in First-Line BPDCN

Ongoing Phase 2 trial with additional small cohort (8-12 patients planned) sufficient for BLA ...

author_avatar
NASDAQ Market News

Heat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

author_avatar
NASDAQ Market News

$7.95 Billion Magnetic Resonance Imaging Market to 2025 – Global Analysis and Forecasts by Field Strength, Architecture, Application, End User, and Geography

Dublin, Nov. 27, 2018 (GLOBE NEWSWIRE) -- The "Magnetic Resonance Imaging Market to 2025 ...

author_avatar
NASDAQ Market News